PTC
LGND icon

Private Trust Company’s Ligand Pharmaceuticals LGND Stock Holding History

Private Trust Company’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18K Hold
57
– – ﹤0.01% 1845
2026
Q1 		$11.4K Buy
57
+9
+19% +$1.78K ﹤0.01% 1931
2025
Q4 		$9.07K Hold
48
– – ﹤0.01% 1975
2025
Q3 		$8.5K Buy
+48
New +$7.14K ﹤0.01% 1972
2025
Q2 		– Sell
-18
Closed -$1.89K – 2533
2025
Q1 		$1.89K Buy
+18
New +$2.04K ﹤0.01% 2266

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Trust Company's LGND Position: Q2 2026 in Review

Private Trust Company held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 57 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

Private Trust Company first reported a position in LGND in Q1 2025 and has held it in 5 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Private Trust Company held 57 shares of Ligand Pharmaceuticals worth $18K as of Q2 2026.
  • Private Trust Company left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #1845 holding.
  • Private Trust Company first reported a position in Ligand Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.